{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-003064","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2021-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.512715+00:00","generated_at":"2026-06-28T13:05:37.393998+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alector reports Q3 net income $126.6M ($1.56/share) vs loss year-ago; GSK collaboration boosts revenue","bullets":["Collaboration revenue $182.4M (vs $5.9M YoY) driven by $500M upfront from GSK deal.","Cash, cash equivalents & marketable securities $777.9M as of Sep 30, 2021.","Initiated Phase 2 trial of AL001 in ALS patients with C9orf72 mutation; primary endpoint safety & PK/PD.","Sam Jackson, M.D., appointed interim CMO; Linda Rubinstein interim CFO; Elizabeth Garofalo, M.D. joins board.","Net income $126.6M ($1.56 diluted EPS) compared to net loss $52.7M ($0.67 loss) in Q3 2020."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-003064","json":"https://secwatch.observer/filing/0000950170-21-003064.json","markdown":"https://secwatch.observer/filing/0000950170-21-003064.md","text":"https://secwatch.observer/filing/0000950170-21-003064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000095017021003064/0000950170-21-003064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000095017021003064/alec-20211104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T13:05:37.393998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}